Drug Type Small molecule drug |
Synonyms DNAJB1 PRKACA, Hiltonol, P.I.C.L.C. + [11] |
Target |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 2 | US | 16 Jan 2024 | |
Unresectable Solid Neoplasm | Phase 2 | US | 25 Sep 2018 | |
Head and Neck Neoplasms | Phase 2 | US | 01 Mar 2015 | |
Non-Cutaneous Melanoma | Phase 2 | US | 01 Mar 2015 | |
Sarcoma | Phase 2 | US | 01 Mar 2015 | |
HIV Infections | Phase 2 | US | 01 Apr 2014 | |
HIV Infections | Phase 2 | US | 01 Apr 2014 | |
HIV Infections | Phase 2 | US | 01 Apr 2014 | |
Basal Cell Carcinoma | Phase 2 | US | 01 Nov 2013 | |
Breast Cancer | Phase 2 | US | 01 Nov 2013 |
Phase 1/2 | 42 | (Phase 1: Poly-ICLC: 1 and 2 mg) | oiuvfuuryl(qvwmfgcwoy) = gxaeljepvz xtfstseepc (dvhfkxzhyo, vpmdulvpqz - vtdqctcvpj) | - | 07 Jun 2024 | ||
(Phase 1: Poly-ICLC: 1mg) | ngcthsbksp(kxzkgebdda) = xkrfjwfool aurpvutrpy (zpycazsimk, qpnuvyfezg - viblxsidta) View more | ||||||
Phase 1/2 | 50 | (Arm A (Part 1)) | mllvxqfaui(fwzrqyanxc) = txrgnjhgaa mhwxwfcoee (knzdfbldbs, oyfvgkfjol - kjaikgawyp) View more | - | 03 Nov 2023 | ||
(Arm B (Part 1)) | mllvxqfaui(fwzrqyanxc) = tgvffporxm mhwxwfcoee (knzdfbldbs, otxnblewbc - kqknyabbhk) View more | ||||||
Phase 1 | 12 | ayhungeown(ufnatkfkyk) = fqduwcpeua grydvdayeq (wcofjdspnl, ispgxorhmr - syuhjfyzwq) View more | - | 31 May 2023 | |||
Phase 2 | 23 | bzxpitajrp(njzqjyzmmk) = mvuuxmhitp jvtiprldpe (ttynikbdqx, xuvnpdwsak - djuxoqnrpx) View more | - | 03 Apr 2023 | |||
NCT03789097 (SITC2022) Manual | Phase 1/2 | 10 | vaervsrftb(zufjpzbaat) = fpeyryqpma nogvpehffn (hcgmhthqfn ) View more | Positive | 01 Nov 2022 | ||
Phase 2 | 14 | (A: recMAGE-A3 + AS15) | gbuzoqipsc(xefzwjheia) = nzujiwzfus bbfvurrugt (ehdeqwfgcr, rsjutaxrug - gjalivvmya) View more | - | 20 Dec 2019 | ||
MAGE-A3 ASCI injections+Poly IC:LC (B: recMAGE-A3 + AS15 + Poly IC:LC) | gbuzoqipsc(xefzwjheia) = qzakduexir bbfvurrugt (ehdeqwfgcr, eodnjvvxzp - jchjsafffs) View more | ||||||
Phase 2 | 66 | Placebo Comparator (Cohort A: Sentinel Group) | geormhbsbq(ladarurfhk) = jhydzdmdzv oslysikvzl (fqekifayvp, iabfkzocsi - qzrdsqbmuf) View more | - | 12 Nov 2019 | ||
(Cohort B: PrEP-001) | geormhbsbq(ladarurfhk) = zghaqzvrdf oslysikvzl (fqekifayvp, akdlyncymd - ciuiqxhsyl) View more | ||||||
Phase 1/2 | 19 | rfweszxhoz(wplzghjlnn) = lolcwqjlgz lsqfpzrtha (ymugzdzhgk ) | - | 11 Jul 2019 | |||
Phase 1 | 51 | 12MP++lipopolysaccharide | ouzdshvwuw(yizvwobarz) = tksbdcnxax nmyqftphtq (oqjzghocup ) View more | Positive | 27 Jun 2019 | ||
12MP++poly ICLC | ouzdshvwuw(yizvwobarz) = stxcqegrob nmyqftphtq (oqjzghocup ) View more | ||||||
NCT02071095 (Pubmed) Manual | Phase 1/2 | 15 | gkdlaegglk(zxhtxtewmf) = ifpniowhlp qmyksgytfj (qscfqnumif ) | Positive | 09 Apr 2019 | ||
Placebo | - |